Fetal Alcohol Spectrum Disorders: Concepts, Mechanisms, and Cure

$360.00

Sushil K. Sharma, Ph.D.
Academic Dean, American International School of Medicine (AISM), Georgetown, Guyana, South America, US Corporate Headquarters, Stone Mountain, Georgia, USA

Series: Neurology – Laboratory and Clinical Research Developments
BISAC: MED056000

Alcoholism exerts a high genetic as well as epigenetic load and may be regarded as one of the most prevalent, identifiable, and preventable neuropsychiatric illnesses afflicting modern society today. Alcohol constituted 3.2% of all worldwide deaths in the year 2006 and is associated with >60 diseases, including fetal alcohol spectrum disorder (FASD), cancers, cardiovascular diseases, liver cirrhosis, neuropsychiatric disorders and life-threatening injuries.

Fetal alcohol spectrum disorder (FASD) is a collective term representing fetal abnormalities associated with maternal alcohol abuse. FASD is a devastating developmental disorder resulting from alcohol exposure during fetal development. It is a considerable public health problem worldwide and is characterized by CNS abnormalities, dysmorphic facial features, and growth deficiency.

Although it is well-established that intra-uterine alcohol exposure can lead to FASD, characterized by cognitive and behavioral impairments, alcohol abuse is still highly prevalent and contributes to a significant loss of economy and productivity throughout the entire world. Children with FASD become a serious and persistent socioeconomic burden to society, as they require specialized healthcare liabilities throughout their entire lives as a consequence of their parents’ irresponsible drinking behavior.

The primary aim of the inter-disciplinary and integrated genome research network (consisting of molecular biologists, psychopharmacologists, system biologists with mathematicians, human geneticists, and clinicians) is to better understand the genetics and epigenetics of alcohol addiction by identifying candidate genes and molecular mechanisms involved in the etiopathogenesis of FASD, and to provide recommendations to the government and scientific community for global dissemination of emerging knowledge and implementation of FASD interventions.

In Fetal Alcohol Spectrum Disorder: Concepts, Mechanisms, and Cure, the author has presented the novel concept of charnolopharmacology, which plays a crucial role in determining the life and death of the fetus during intrauterine fetal alcohol exposure (FAE). More specifically, it proposes mitochondrial bioenergetics-based charnolopharmacotherapeutics for personalized theranostics of FASD, involving diversified charnolopathies, embryopathies, and infertility; resulting in poor quality of life.

Although several concepts, mechanisms and potential therapies have been proposed recently to overcome the deleterious consequences of FASD, the author has now proposed charnolopharmacotherapeutics, which is based on ethanol-induced compromised mitochondrial bioenergetics and the induction of charnolopathies initially in the spermatocyte and oocyte during the prezygotic phase, and subsequently in the neural progenitor cells (NPCs) during the post-zygotic phase of pregnancy. Hence, drugs inhibiting CB formation and/or augmenting charnolophagy as a basic molecular mechanism of intracellular detoxification during the acute phase, stabilizing charnolophagosome and preventing charnolosome sequestration and budding during chronic phase, will have therapeutic potential in FASD embryopathies, which is elegantly described in this book.

The most unique feature of this book is that it introduces original concepts of mitochondrial bioenergetics, genomics, and epigenomics to successfully manage FASD. Particularly, mitochondrial bioenergetics-based CB prevention/inhibition, charnolophagy induction, and charnolophagosome and charnolosome stabilization are novel therapeutic targets for safe and effective clinical management of FASD. These concepts and mechanisms are based on several years of basic research and original discoveries by the author. (Imprint: Nova Biomedical)

Clear

Details

Table of Contents

Main Message

Words of Wisdom

Acknowledgement

About this Book

About the Author

Abbreviations

Definitions

Preface

PART I. Introduction

Chapter 1. Alcohol Addiction (Basic Background)

Chapter 2. Global Incidence of Fetal Alcohol Syndrome

Chapter 3. FASD and Loss of Economy and Productivity

Chapter 4. Fetal Alcohol Spectrum Disorder (Historical Perspective and Clinical Symptoms)

Chapter 5. FASD and Other Mental Health Disorders

Part II. Molecular Mechanisms of FASD

Chapter 6. Molecular Mechanisms of FASD

Chapter 7. Conventional and Potential FASD Biomarkers

Chapter 8. Pharmacogenomics of FASD

Chapter 9. Epigenetics of FASD (Part-1)

Chapter 10. Epigenetics of FASD (Part-2)

Chapter 11. Microarray Analyses of FASD

Part III. Basic Concepts of FASD

Chapter 12. Clinical Significance of Charnoly Body (CB) in FASD

Chapter 13. CB Pathogenesis of FASD (A Compromised Charnolophagy in FASD)

Chapter 14. Mitochondrial Bioenergetics of FASD (Recent Update)

Chapter 15. Clinical Significance of Charnolophagy in FASD

Chapter 16. Micro-RNA and FASD

Chapter 17. Clinical Benefits of Animal Models in FASD

Part IV. Recent Experimental Studies on FASD

Chapter 18. In-Vitro Experimental Models of FASD

Chapter 19. Emerging Cellular and Molecular Mechanisms of FASD

Chapter 20. Cerebral Organoids and Cell Culture Studies of FASD

Chapter 21. Emerging Molecular Mechanisms of Neurotoxicity of FASD

Chapter 22. FASD: Recent Update

Part V. FASD Neuroprotection and Treatment

Chapter 23. Molecular Mechanisms of Neuroprotection in FASD

Chapter 24. Fetal Alcohol Spectrum Disorder (FASD) Prevention, Diagnosis, and Treatment

Chapter 25. Prevention and Treatment of FASD (Recent Update)

Index


Additional Information

This book provides basic and applied knowledge about FASD, its basic molecular mechanism of occurrence during prezygotic and postzygotic phase due to Ethanol-induced diversified charnolopathies. Basic knowledge of emerging charnolopharmacotherapeutics is provided for the safe and effective clinical management of FASD. The book will be valuable source of new knowledge for doctors, patients, medical students, teachers, researchers, and basic biomedical scientists.

The book will be highly useful for general public interested in learning more about FASD without any misconception and/or misunderstanding for its prevention and/or treatment to prevent chronic diseases, early morbidity, and mortality.

Neonatologists, Pediatricians, Neurologist, and Neuropsychiatrists will find this book interesting for the effective clinical management of FASD victims. The book will be of immediate interest to FASD parents and FASD victims to alleviate their sufferings.

Physicians interested in prescribing and learning more about FASD and their molecular and pharmacological mechanism(s) of neuroprotection will find this book high beneficial. They will be highly benefited from its informative and basic and clinically-interesting contents.

In general, the book will be a valuable source of knowledge for the basic researcher, clinically useful for the physician, and therapeutically-beneficial for FASD patients and their families.

In addition to physicians, the book can be a valuable for Masters and Ph. D students interested in conducting further research on FASD for the effective clinical management of various associated neurological and psychiatric disorders like ADHD in these patients.

Particularly, MD doctors, students, and professors will find this book interesting and informative to enhance their basic existing knowledge about FASD and its prevention and/or treatment for a better quality of life.

Additional information

Binding

,